Study of Dapagliflozin to Prevent Acute Graft-versus-Host Disease in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation with Haploidentical or Unrelated Donors

What this Trial Is About

Researchers are evaluating whether Dapagliflozin can help prevent acute graft-versus-host disease aGVHD in patients undergoing allogeneic hematopoietic cell transplantation allo-HCT from haploidentical or unrelated donors. This study aims to understand if taking Dapagliflozin daily lowers the chances of developing aGVHD and to monitor safety and medical issues during this treatment. The trial is a phase 2, single-arm study led by The First Affiliated Hospital of Soochow University. Participants will take 10 mg of Dapagliflozin each day from one day before transplantation up to 14 days after. This treatment period is designed to assess the effect of Dapagliflozin on preventing aGVHD after allo-HCT. No placebo or comparison group is used all enrolled participants receive the drug. During the study, researchers will monitor the occurrence and severity of aGVHD up to 100 days after transplantation, as well as the recovery of neutrophils and platelets, survival rates, relapse rates, and chronic graft-versus-host disease over one year. Safety will be evaluated by tracking treatment-related severe side effects up to 100 days. Participants will be followed closely during these periods to collect clinical data and assess outcomes related to the transplantation and the study drug.

Dapagliflozin in Allo-HCT for aGVHD